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Abstract A 62-year-old man was admitted to hospital for
elective revision of a left total hip arthroplasty. His history
was significant for human immunodeficiency virus (HIV)
infection for which he was taking the following antiretro-
viral agents (ARVs): etravirine, ritonavir, darunavir, ral-
tegravir and tenofovir/emtricitabine. Rivaroxaban 10 mg
daily was commenced on the second postoperative day for
venous thromboembolism (VTE) prophylaxis. Approxi-
mately 24 h later, the patient developed hypotension and
anaemia, accompanied by thigh swelling due to bleeding at
the surgical site. Fluid resuscitation was commenced with
red cell transfusion. The prothrombin time (PT) was pro-
longed at 24.3 (10.6–15.3) s, and a rivaroxaban level taken
24 h after administration was 75 ng/mL. Rivaroxaban was
ceased, the PT normalised within 24 h of stopping the
drug, and the patient made an uneventful recovery. None of
the other coadministered drugs are known to interact with
rivaroxaban, or are likely to, based on their metabolic
pathways. Rivaroxaban, a substrate for cytochrome P450
(CYP) 3A4 and P-glycoprotein (P-gp), is contraindicated in
patients concomitantly treated with strong inhibitors of
both these systems, e.g. protease inhibitors (PIs) such as
ritonavir (based on in vitro data and a pharmacokinetic
study in healthy volunteers). No published data are avail-
able on the PI darunavir, a moderate inhibitor; however,
concomitant use with rivaroxaban should also be avoided.
A prolonged PT and a rivaroxaban trough level greater than
eight times that predicted from pharmacokinetic modelling
suggests that bleeding was due to increased exposure to
rivaroxaban, probably due to an interaction with ritonavir
and darunavir. This is supported by a Drug Interaction
Probability Scale (DIPS) score of 8. An interaction
between a single dose of rivaroxaban and ARVs may be
clinically significant; therefore, the patient’s medication
history should be extensively evaluated to identify any
potential interactions.
Key Points
Drug interactions with rivaroxaban are a potential
cause for serious adverse effects.
An interaction between a single dose of rivaroxaban
and protease inhibitors may result in bleeding.
Extensive evaluation of the interaction profile is
essential prior to adding rivaroxaban to antiretroviral
therapy.
Introduction
A recent study by McDonald et al. showed that a large
proportion of spontaneous reports of adverse events with
rivaroxaban were associated with concomitant medicines,
which may have increased the risk [1]. The authors con-
cluded that there is a need for ongoing postmarketing
surveillance of rivaroxaban, together with an increased
awareness of the potential for drug interactions as a cause
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for serious adverse events. However, there was no mention
of reports of interactions with antiretroviral agents (ARVs).
We would like to describe a case report that illustrates the
rapid effect of an interaction between the target-specific
oral anticoagulant (TSOAC) rivaroxaban and ARVs.
Case Report
A 62-year-old male orthopedic surgical patient receiving
long-term ARVs was commenced on enoxaparin 40 mg
subcutaneously daily for venous thromboembolism (VTE)
prophylaxis 3 weeks preoperatively. Preadmission medica-
tions that were continued postoperatively included the
ARVs, etravirine 200 mg twice daily, ritonavir 100 mg
twice daily, darunavir 600 mg twice daily, raltegravir
400 mg twice daily and emtricitabine/tenofovir 300/200 mg
daily; mirtazapine 45 mg at night, aspirin 100 mg in the
morning, esomeprazole 20 mg daily, valaciclovir 500 mg
daily, and oxycodone sustained-release 60 mg twice daily.
New medications that were commenced postoperatively
included intravenous prophylactic antibiotics, meropenem
1000 mg three times daily and linezolid 600 mg twice daily
for 1 week, and a single dose of antifungal therapy, oral
fluconazole 400 mg. Pain was managed with pregabalin
75 mg twice daily, ketamine intravenous infusion up to
16 mg/h and morphine patient-controlled analgesia. Post-
operatively, enoxaparin was replaced with rivaroxaban
10 mg daily. Twenty-four hours after concomitant admin-
istration of rivaroxaban with ARVs, the patient experienced
profound hypotension and bleeding at the surgical site. At
the time of bleeding, laboratory results showed a prolonged
prothrombin time (PT) of 24.3 (10.6–15.3) s and a signifi-
cantly elevated rivaroxaban trough level of 75 ng/mL (me-
dian plasma concentration 24 h after a 10 mg dose has been
reported to be 9 ng/mL) [2]. Renal function was normal.
Rivaroxaban was ceased and the patient was managed with
fluid resuscitation, packed red blood cells, fresh frozen
plasma and human prothrombin complex (Prothrombinex-
VF). No further bleeding occurred and 24 h later PT had
normalized and the rivaroxaban level had decreased to
11 ng/mL. Enoxaparin for VTE prophylaxis was com-
menced 1 week later.
Discussion
Rivaroxaban, a substrate for cytochrome P450 (CYP) 3A4
and P-glycoprotein (P-gp), is contraindicated in patients
concomitantly treated with strong inhibitors of both these
systems, e.g. protease inhibitors (PIs) such as ritonavir [3].
The PI darunavir, a moderate CYP3A4 inhibitor, should
also be avoided in patients receiving rivaroxaban [4, 5].
This recommendation is based on in vitro data and a
pharmacokinetic study in healthy volunteers of rivaroxaban
coadministered with drugs that share its metabolic path-
way, e.g. ritonavir, midazolam [6]. Our patient was taking
six ARVs, including the two PIs ritonavir and darunavir,
and one non-nucleoside reverse-transcriptase inhibitor
(NNRTI), etravirine (a moderate CYP3A4 inducer) [4]. No
clinically significant interactions were expected to occur
with the other ARVs, i.e. the integrase inhibitor, raltegravir
and the nucleoside reverse-transcriptase inhibitors (NRTIs)
emtricitabine/tenofovir [5].
After oral administration of a CYP3A4 inhibitor such as
ritonavir, there is a rapid increase in the substrate plasma
level, which is reversible, typically within 2–3 days of
stopping the inhibitor [7]. Ritonavir is used as a pharma-
cokinetic booster and is included in most PI-based regi-
mens at the lower dose of 100 mg twice daily compared
with the 600 mg twice-daily regimen when used for its
antiviral activity [4]. In this setting, ritonavir is a phar-
macologic enhancer because it inhibits the metabolism of
coadministered PIs, resulting in an increase in blood and
tissue levels. Administration of a single dose of rivaroxa-
ban 10 mg to healthy volunteers taking steady-state riton-
avir 600 mg twice daily has been shown to increase the
area under the curve (AUC) by 153 % and the mean
maximum concentration (Cmax) by 55 % [6]. No pharma-
cokinetic data are available on the impact of lower doses of
ritonavir, i.e. 100 mg twice daily coadministered with
rivaroxaban. In addition, no published data are available on
the clinical significance of the interaction potential of
darunavir, but the recommendation to avoid concomitant
administration with rivaroxaban is similar to ritonavir [5].
Since the registration of rivaroxaban in Australia, in
2008 to November 2014 no reports, in addition to the one
presented here, have been submitted to the Australian
regulatory authority for therapeutic goods—the Therapeu-
tics Goods Administration (TGA)—on adverse effects
resulting from an interaction between rivaroxaban and
ARVs [8]. To our knowledge, there is only one published
case describing clinically significant bleeding possibly
associated with an interaction between rivaroxaban and
ARVs, including ritonavir, darunavir and etravirine [9];
however, a causal relationship between the adverse event
and the drug interaction is unclear.
The clinical significance of an interaction between
rivaroxaban and etravirine, a moderate CYP3A4 inducer, is
not known. Induction of CYP3A4 is not an instantaneous
process and may take 2–3 weeks to reach steady state [10].
Our patient had been taking etravirine for a number of
years, therefore maximal induction was already present.
The concomitant administration of rivaroxaban and etra-
virine may have decreased rivaroxaban levels to some
extent and may have attenuated its effect.
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Other drugs such as fluconazole may interact with
rivaroxaban; however, it is a moderate inhibitor of
CYP3A4 and, potentially, Bcrp (ABCG2). In the study by
Mueck et al., only a modest increase in rivaroxaban blood
level was observed after 4 days of pretreatment with flu-
conazole [6]. Our patient had only received one dose of
fluconazole, therefore it is not likely to have had an impact
on rivaroxaban levels.
None of the other coadministered drugs are known to, or
are likely to, interact with rivaroxaban based on their
metabolic pathway, i.e. ketamine, morphine.
For TSOACs, routine coagulation tests can be useful as
screening tests to determine residual anticoagulant effect in
certain clinical situations, such as the presence of bleeding
[11]. The PT is the most sensitive assay for detecting
rivaroxaban; however, it can be influenced by a number of
factors, including hepatic impairment, sepsis, trauma with
significant blood loss and laboratory PT reagent (throm-
boplastin) sensitivity [12].
The clinical relevance of TSOAC drug levels is
unknown and should not be used to improve effectiveness
[13]. However, in the presence of TSOAC-associated
bleeding, specific drug levels should be performed, in
conjunction with appropriate coagulation testing, to assess
the contribution of excess drug to the bleeding event and to
guide the need for intervention. In patients undergoing hip
replacement surgery, the median rivaroxaban plasma con-
centration after a 10 mg once-daily dose was 9 ng/ml 24 h
after the dose, i.e. trough level [2].
In our patient, the presence of a trough rivaroxaban level
more than eight times higher than that expected from
published data, together with a prolonged PT, suggests that
bleeding may have been associated with increased expo-
sure to the anticoagulant [2]. The rapid onset of bleeding
and subsequent normalization of PT upon discontinuation
of rivaroxaban is consistent with the pharmacokinetics of
the drug and an interaction with ritonavir, which has been
described in vitro and in healthy volunteers, and also with
darunavir, based on its metabolic pathway. This is sup-
ported by a Drug Interaction Probability Scale (DIPS) score
of 8, indicating a probable association [14].
Conclusions
Prescribers and pharmacists need to be alert to the potential
for this clinically significant interaction to occur and to use
the combination of TSOACs and ARV regimens containing
PIs with caution. Due to the potentially serious conse-
quences, for patients on ARVs it may be prudent to con-
sider alternative agents for VTE prophylaxis, such as low-
molecular-weight heparin, until an extensive evaluation of
the interaction profile has been performed. Specialized
resources for checking interactions with ARVs are readily
available [5].
Written informed consent was obtained from the patient
prior to publication of this case report.
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